Payment overview · 2025
General Payments
$88.76
5 reported records · 3 companies
Healthcare provider profile · identity verified
Bradley S. Patterson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COVINGTON, KY · NPI 1770690216
Verified facts
What the public records show
CMS Open Payments records show Bradley S. Patterson, M.D. received $88.76 in general payments during 2025 across 5 reported records.
PFIZER INC. accounted for 41.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.86 | 41.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.15 | 37.4% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.75 | 21.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $88.76 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.86 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.15 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 167 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 659 | 189 |
| Gabapentin | Gabapentin | 613 | 107 |
| Lisinopril | Lisinopril | 403 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 368 | 109 |
| Omeprazole | Omeprazole | 368 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 362 | 100 |
| Simvastatin | Simvastatin | 336 | 92 |
| Metformin Hcl | Metformin Hcl | 294 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 274 | 81 |
| Trazodone Hcl | Trazodone Hcl | 259 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 251 | 83 |
| Tizanidine Hcl | Tizanidine Hcl | 235 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 70 |
| Losartan Potassium | Losartan Potassium | 217 | 65 |
| Furosemide | Furosemide | 216 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 208 | 44 |
| Prednisone | Prednisone | 199 | 150 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 179 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 47 |
| Eliquis | Apixaban | 167 | 42 |
| Allopurinol | Allopurinol | 160 | 39 |
| Montelukast Sodium | Montelukast Sodium | 145 | 38 |
| Metformin Hcl Er | Metformin Hcl | 142 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 42 |
| Potassium Chloride | Potassium Chloride | 126 | 43 |
| Mirtazapine | Mirtazapine | 124 | 39 |
| Celecoxib | Celecoxib | 121 | 46 |
| Lorazepam | Lorazepam | 121 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 35 |
| Spironolactone | Spironolactone | 116 | 38 |
| Meloxicam | Meloxicam | 113 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 110 | 33 |
| Buspirone Hcl | Buspirone Hcl | 104 | 30 |
| Carvedilol | Carvedilol | 99 | 32 |
| Clonazepam | Clonazepam | 97 | 18 |
| Glimepiride | Glimepiride | 97 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 23 |
| Farxiga | Dapagliflozin Propanediol | 88 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 24 |
| Azithromycin | Azithromycin | 75 | 64 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 19 |
| Famotidine | Famotidine | 74 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 18 |
| Torsemide | Torsemide | 72 | 24 |
| Tramadol Hcl | Tramadol Hcl | 69 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 68 | 19 |
| Sertraline Hcl | Sertraline Hcl | 68 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 17 |
| Doxepin Hcl | Doxepin Hcl | 65 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 16 |
| Alendronate Sodium | Alendronate Sodium | 64 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 53 |
| Ozempic | Semaglutide | 59 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 22 |
| Atenolol | Atenolol | 53 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 47 |
| Ondansetron Odt | Ondansetron | 53 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 13 |
| Xarelto | Rivaroxaban | 51 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 50 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 16 |
| Warfarin Sodium | Warfarin Sodium | 48 | 15 |
| Fluconazole | Fluconazole | 47 | 27 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 47 | 19 |
| Synthroid | Levothyroxine Sodium | 47 | 14 |
| Januvia | Sitagliptin Phosphate | 45 | 11 |
| Jardiance | Empagliflozin | 44 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 42 | 15 |
| Alprazolam | Alprazolam | 41 | 11 |
| Ibuprofen | Ibuprofen | 41 | 13 |
| Methocarbamol | Methocarbamol | 41 | 17 |
| Cephalexin | Cephalexin | 38 | 34 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 13 |
| Nystatin | Nystatin | 35 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 12 |
| Azelastine Hcl | Azelastine Hcl | 34 | 15 |
| Bupropion Xl | Bupropion Hcl | 34 | 11 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 20 |
| Clonidine Hcl | Clonidine Hcl | 33 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Cefdinir | Cefdinir | 31 | 29 |
| Klor-Con M20 | Potassium Chloride | 31 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 13 |
| Linzess | Linaclotide | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 24 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | 12 |
| Cefuroxime | Cefuroxime Axetil | 21 | 19 |
| Indomethacin | Indomethacin | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Baclofen | Baclofen | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Anastrozole | Anastrozole | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $88.76 · 5 records | PFIZER INC. | ELIQUIS, Heplisav-B, NURTEC ODT, QULIPTA, UBRELVY, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error